Company News 

Eco Animal Health looks beyond Aivlosin

Eco Animal Health looks beyond Aivlosin

It seems that soaring sales of Eco Animal Health’s (EAH) key antibiotic product – Aivlosin – are no longer enough to satisfy the market. Despite a 14 per cent increase in revenues from the drug in the year to March 2018, and further regulatory approvals that will allow its sale in new markets, the group’s share price has fallen 13 per cent since it reported its last set of annual results – a sharp reversal from the 110 per cent share price growth in the two years to July 2017.

To continue reading, subscribe today

and enjoy unlimited access to the following:

  • Tips of the Week
  • Funds coverage
  • Weekly features on big investment themes
  • Trading ideas
  • Comprehensive companies coverage
  • Economic analysis
Subscribe
Subscribe to Investors Chronicle

Subscribe today

Full access for just £3.37 a week:

• Tips and recommendations - to beat the market 
• Portfolio clinic & Mr Bearbull - build a well-planned portfolio 
• Expert tools - track and manage investments effortlessly
• Plus free delivery to your home or office

Subscribe Now